A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy
4 affiliations
- 1CSPC Pharmaceutical Group Limited, Shijiazhuang 050035, P.R. China
- 2School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
- 3Department of Emergency and Critical Care Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu 215000, China
- 4Shanghai Pudong Hospital, State Key Laboratory of Genetics and Development of Complex Phenotypes, Department of Biochemistry and Biophysics, School of Life Sciences, Fudan University, Shanghai 200438, P.R. China
Abstract
Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is pathologically characterized by excessive complement activation. While multiple therapeutic approaches have been explored for IgAN, efficacious complement-targeted therapies for clinical use are still scarce. In the present work, we describe the preclinical profile of a N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting complement component 5 (C5) for the treatment of IgAN. This C5-siRNA exhibited picomolar inhibitory activity in vitro, with an IC50 value of 0.013 nM. In cynomolgus non-human primates, a single subcutaneous injection yielded sustained C5 suppression of over 80% for 2 months and more than 50% for up to 4 months, a duration significantly longer than is possible with existing complement inhibitors. Furthermore, we conducted a head-to-head efficacy comparison with Nefecon, an approved therapeutic agent for IgAN, in a cynomolgus monkey IgAN model. While both treatments showed comparable improvements in key renal function parameters, the C5-siRNA achieved superior pathological remission and near-complete blockade of glomerular C5 deposition and membrane attack complex formation. Collectively, this study provides a strong rationale for the clinical development of C5-siRNA as an excellent therapy for IgAN, either as a standalone monotherapy or in combination with agents targeting upstream pathogenic pathways.
Related
- A Deformulating Multi-Attribute SEC Method for Simultaneous Quantification of Total RNA, Conjugated Antibody, and Free Antibody in Targeted Lipid Nanoparticles
- Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke
- A Multidimensional Engineering Strategy Reprograms Microglia via Targeted and Sustained‐Release Extracellular Vesicles for Spinal Cord Injury Repair
- Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model
- Influence of antibody-antigen interaction on fluorescence of Rhodamine 6G conjugated to the antibodies measured in human serum
BibTeX
@article{zhang2026complement,
title = {{A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy}},
author = {Xueyan Zhang and Xue Zhang and Qiuyu Yang and Bin Kang and Mo Dan and Chunlei Li and Yan Chen and Jianhua Gan and Xiaoye Su},
journal = {Molecular Therapy},
year = {2026},
month = aug,
doi = {10.1016/j.ymthe.2026.08.022},
url = {https://doi.org/10.1016/j.ymthe.2026.08.022},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy
AU - Xueyan Zhang
AU - Xue Zhang
AU - Qiuyu Yang
AU - Bin Kang
AU - Mo Dan
AU - Chunlei Li
AU - Yan Chen
AU - Jianhua Gan
AU - Xiaoye Su
PY - 2026
DA - 2026/08/13
JO - Molecular Therapy
DO - 10.1016/j.ymthe.2026.08.022
UR - https://doi.org/10.1016/j.ymthe.2026.08.022
AB - Immunoglobulin A nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is pathologically characterized by excessive complement activation. While multiple therapeutic approaches have been explored for IgAN, efficacious complement-targeted therapies for clinical use are still scarce. In the present work, we describe the preclinical profile of a N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting complement component 5 (C5) for the treatment of IgAN. This C5-siRNA exhibited picomolar inhibitory activity in vitro, with an IC50 value of 0.013 nM. In cynomolgus non-human primates, a single subcutaneous injection yielded sustained C5 suppression of over 80% for 2 months and more than 50% for up to 4 months, a duration significantly longer than is possible with existing complement inhibitors. Furthermore, we conducted a head-to-head efficacy comparison with Nefecon, an approved therapeutic agent for IgAN, in a cynomolgus monkey IgAN model. While both treatments showed comparable improvements in key renal function parameters, the C5-siRNA achieved superior pathological remission and near-complete blockade of glomerular C5 deposition and membrane attack complex formation. Collectively, this study provides a strong rationale for the clinical development of C5-siRNA as an excellent therapy for IgAN, either as a standalone monotherapy or in combination with agents targeting upstream pathogenic pathways.
SN - 1525-0016
SN - 1525-0024
ER -